LivaNova PLC (NASDAQ:LIVN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Thursday. The brokerage currently has a $89.00 price target on the stock. Zacks Investment Research‘s price objective points to a potential upside of 10.19% from the company’s previous close.
According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “
A number of other research analysts also recently weighed in on LIVN. BidaskClub downgraded LivaNova PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Berenberg Bank reissued a “buy” rating and issued a $70.00 price target on shares of LivaNova PLC in a research note on Friday, August 11th. WBB Securities downgraded LivaNova PLC from a “hold” rating to a “sell” rating and set a $50.00 price target on the stock. in a research note on Tuesday, August 15th. Needham & Company LLC initiated coverage on LivaNova PLC in a research note on Wednesday, August 23rd. They issued a “hold” rating on the stock. Finally, Jefferies Group LLC initiated coverage on LivaNova PLC in a research note on Friday, September 8th. They issued a “buy” rating and a $76.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $77.86.
LivaNova PLC (LIVN) opened at $80.77 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.03 and a quick ratio of 1.42. The firm has a market capitalization of $3,890.19, a price-to-earnings ratio of 23.25, a PEG ratio of 2.42 and a beta of 0.52. LivaNova PLC has a 12 month low of $40.83 and a 12 month high of $81.85.
LivaNova PLC (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.17. The company had revenue of $309.70 million for the quarter, compared to the consensus estimate of $301.22 million. LivaNova PLC had a return on equity of 9.33% and a net margin of 4.63%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.78 EPS. sell-side analysts forecast that LivaNova PLC will post 3.33 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “LivaNova PLC (LIVN) Upgraded to “Buy” at Zacks Investment Research” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/09/livanova-plc-livn-upgraded-to-buy-at-zacks-investment-research.html.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $68.55, for a total transaction of $68,550.00. Following the sale, the director now owns 57,296 shares of the company’s stock, valued at approximately $3,927,640.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 3,000 shares of company stock worth $203,890 in the last ninety days. 0.28% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its stake in LivaNova PLC by 9.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after buying an additional 153 shares during the period. Riverhead Capital Management LLC raised its stake in LivaNova PLC by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock worth $108,000 after buying an additional 763 shares during the period. Exane Derivatives raised its stake in LivaNova PLC by 814.8% during the 2nd quarter. Exane Derivatives now owns 3,156 shares of the company’s stock worth $158,000 after buying an additional 2,811 shares during the period. Teacher Retirement System of Texas acquired a new stake in LivaNova PLC during the 2nd quarter worth $204,000. Finally, LS Investment Advisors LLC raised its stake in LivaNova PLC by 14.5% during the 2nd quarter. LS Investment Advisors LLC now owns 3,449 shares of the company’s stock worth $211,000 after buying an additional 436 shares during the period. 81.69% of the stock is currently owned by institutional investors and hedge funds.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.